Health & Fitness
Health and FitnessHealth and Fitness 
Tue, June 28, 2011
Mon, June 27, 2011
Immunovaccine to Present at the 2011 BIO Business Forum
HALIFAX, June 27, 2011 /CNW/ - Immunovaccine Inc. (TSX-V:IMV), a clinical stage vaccine development company, announced that Dr. Marc Mansour, Chief Operating Officer and Chief Science Officer, will be presenting at the 2011 Biotechnology Industry Organization (BIO) Business Forum. Dr. Mansour's presentation will be on Thursday, June 30 at 9:45 a.m. EDT in the Adams Morgan Room at the Walter E. Washington Convention Center in Washington, DC.
The presentation will include an overview of the Company with emphasis on the Company's patented DepoVax™ vaccine delivery platform. Dr. Mansour will also provide a clinical update on its two vaccine candidates, DPX-0907 and DPX-Survivac.
For DPX-0907, a Phase I study demonstrated that the vaccine was safe and successfully elicited an antigen specific immune response for patients with breast, ovarian, or prostate cancer. For DPX-Survivac, a survivin-based therapeutic cancer vaccine, Immunovaccine has recently received FDA clearance to begin a Phase I/II clinical trial in patients with ovarian cancer.
The BIO International Convention is the largest global event for the biotechnology industry, offering networking and partnering opportunities. For further information about the 2011 BIO International Business Forum visit [ http://convention.bio.org/businessforum ].
About Immunovaccine
Immunovaccine Inc. is a clinical stage vaccine development company focused on the commercialization of its DepoVax™ vaccine delivery platform and product candidates. The DepoVax platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance the immune response. Immunovaccine continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. [ www.imvaccine.com ]
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.